[The REALIST (REsiduAl risk, LIpids and Standard Therapies) study: an analysis of residual risk attributable to lipid profile in acute coronary syndrome]

Endocrinol Nutr. 2011 Jan;58(1):38-47. doi: 10.1016/j.endonu.2010.10.004. Epub 2011 Jan 3.
[Article in Spanish]

Abstract

The R3i Foundation (Residual Risk Reduction Initiative), an independent, multinational and academic organization, is conducting the REALIST (Residual Risk, Lipids and Standard Therapies) study in 40 centers in different countries. This is a retrospective epidemiological study, designed to provide new data on the residual risk of major coronary events attributable to lipid abnormalities in patients receiving the current standard treatment. The initial results are expected in mid 2010, and the overall results at the end of 2010.

Publication types

  • English Abstract
  • Multicenter Study

MeSH terms

  • Acute Coronary Syndrome / blood*
  • Acute Coronary Syndrome / etiology
  • Aged
  • Aged, 80 and over
  • Atherosclerosis / blood
  • Atherosclerosis / drug therapy
  • Atherosclerosis / etiology
  • Cardiovascular Diseases / blood
  • Cardiovascular Diseases / epidemiology*
  • Case-Control Studies
  • Cholesterol, HDL / blood
  • Cholesterol, LDL / blood
  • Dyslipidemias / blood
  • Dyslipidemias / complications*
  • Dyslipidemias / drug therapy
  • Female
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
  • Hypertriglyceridemia / blood
  • Hypertriglyceridemia / complications
  • Hypertriglyceridemia / drug therapy
  • International Cooperation
  • Lipids / blood*
  • Male
  • Medical Records / statistics & numerical data
  • Meta-Analysis as Topic
  • Middle Aged
  • Patient Selection
  • Recurrence
  • Retrospective Studies
  • Risk
  • Risk Assessment

Substances

  • Cholesterol, HDL
  • Cholesterol, LDL
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Lipids